

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Financial Report
June 30, 2021

Contents

Independent auditor's report	1
<hr/>	
Financial statements	
Balance sheets	2
Statements of activities	3
Statement of functional expenses	4
Statements of cash flows	5
Notes to financial statements	6-21



RSM US LLP

Independent Auditor's Report

Board of Directors
Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Report on the Financial Statements

We have audited the accompanying financial statements of Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation (the Foundation), which comprise the balance sheets as of June 30, 2021 and 2020, the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

RSM US LLP

New York, New York
October 20, 2021

Cancer Research Fund of the Damon Runyon–Walter Winchell Foundation

Balance Sheets
June 30, 2021 and 2020

	2021	2020
Assets		
Cash and cash equivalents	\$ 13,589,551	\$ 14,909,769
Accounts receivable	171,976	130,246
Interest and dividends receivable	-	12,000
Prepaid expenses and other assets	285,307	282,078
Contributions and bequests receivable, net	10,710,143	11,009,219
Investments, at fair value	142,590,768	115,139,591
Amounts held in trust by others	8,033,216	6,386,367
Fixed assets, net	199,693	237,801
	<hr/>	<hr/>
Total assets	\$ 175,580,654	\$ 148,107,071
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 756,781	\$ 801,926
Deferred revenue	557,154	1,037,209
Deposits for theater tickets	897,811	898,011
Fellowships and awards payable	30,350,423	32,784,680
Total liabilities	32,562,169	35,521,826
Net assets:		
Without donor restrictions	123,789,822	96,662,167
With donor restrictions	19,228,663	15,923,078
Total net assets	143,018,485	112,585,245
	<hr/>	<hr/>
Total liabilities and net assets	\$ 175,580,654	\$ 148,107,071

See notes to financial statements.

Cancer Research Fund of the Damon Runyon–Walter Winchell Foundation

Statements of Activities Years Ended June 30, 2021 and 2020

	2021			2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Operating activities:						
Revenue:						
Contributions	\$ -	\$ 12,567,554	\$ 12,567,554	\$ -	\$ 15,002,223	\$ 15,002,223
Theater ticket revenue, net of donor benefit expense	(1,002)	-	(1,002)	181,699	-	181,699
Donated services	396,000	-	396,000	496,375	-	496,375
Bequests, net of related legal fees	-	2,443,007	2,443,007	-	480,247	480,247
Income from amounts held in trust by others	408,094	-	408,094	606,822	-	606,822
Miscellaneous income	569,209	-	569,209	159,406	-	159,406
Investment return allocated to operations	3,954,938	-	3,954,938	4,151,352	-	4,151,352
	<u>5,327,239</u>	<u>15,010,561</u>	<u>20,337,800</u>	<u>5,595,654</u>	<u>15,482,470</u>	<u>21,078,124</u>
Net assets released from restrictions	15,428,101	(15,428,101)	-	16,084,949	(16,084,949)	-
Total operating revenue	<u>20,755,340</u>	<u>(417,540)</u>	<u>20,337,800</u>	<u>21,680,603</u>	<u>(602,479)</u>	<u>21,078,124</u>
Operating expenses:						
Program services:						
Scientific awards:						
Fellowships awards	6,706,100	-	6,706,100	6,311,080	-	6,311,080
Sohn pediatric awards	8,526	-	8,526	378,368	-	378,368
Physician-scientist awards	1,437,476	-	1,437,476	2,195,228	-	2,195,228
Quantitative biology awards	544,705	-	544,705	2,154,471	-	2,154,471
Dale Frey awards	500,000	-	500,000	599,985	-	599,985
Clinical investigator awards	4,562,161	-	4,562,161	3,084,412	-	3,084,412
Rachleff innovation awards	2,448,977	-	2,448,977	3,991,936	-	3,991,936
Total scientific awards	<u>16,207,945</u>	<u>-</u>	<u>16,207,945</u>	<u>18,715,480</u>	<u>-</u>	<u>18,715,480</u>
Other program expense	1,885,025	-	1,885,025	2,085,716	-	2,085,716
Total program services	<u>18,092,970</u>	<u>-</u>	<u>18,092,970</u>	<u>20,801,196</u>	<u>-</u>	<u>20,801,196</u>
Supporting services:						
Management and general	871,406	-	871,406	770,416	-	770,416
Fundraising	1,790,964	-	1,790,964	2,167,350	-	2,167,350
Total supporting services	<u>2,662,370</u>	<u>-</u>	<u>2,662,370</u>	<u>2,937,766</u>	<u>-</u>	<u>2,937,766</u>
Total operating expenses	<u>20,755,340</u>	<u>-</u>	<u>20,755,340</u>	<u>23,738,962</u>	<u>-</u>	<u>23,738,962</u>
Decrease in net assets from operations	<u>-</u>	<u>(417,540)</u>	<u>(417,540)</u>	<u>(2,058,359)</u>	<u>(602,479)</u>	<u>(2,660,838)</u>
Nonoperating activities:						
Investment return greater than amount appropriated for operations	27,127,655	2,161,236	29,288,891	-	383,774	383,774
Change in value of charitable remainder trusts	-	271,473	271,473	-	19,220	19,220
Change in value of perpetual trusts	-	1,290,416	1,290,416	-	(174,955)	(174,955)
Total nonoperating activities	<u>27,127,655</u>	<u>3,723,125</u>	<u>30,850,780</u>	<u>-</u>	<u>228,039</u>	<u>228,039</u>
Change in net assets	<u>27,127,655</u>	<u>3,305,585</u>	<u>30,433,240</u>	<u>(2,058,359)</u>	<u>(374,440)</u>	<u>(2,432,799)</u>
Net assets:						
Beginning	96,662,167	15,923,078	112,585,245	98,720,526	16,297,518	115,018,044
Ending	<u>\$ 123,789,822</u>	<u>\$ 19,228,663</u>	<u>\$ 143,018,485</u>	<u>\$ 96,662,167</u>	<u>\$ 15,923,078</u>	<u>\$ 112,585,245</u>

See notes to financial statements.

Cancer Research Fund of the Damon Runyon–Walter Winchell Foundation

Statement of Functional Expenses

Year Ended June 30, 2021

(With Summarized Comparative Information for the Year Ended June 30, 2020)

	Supporting Services				Total	2020 Summarized Comparative Total
	Program Services	Management and General	Fundraising	Total Supporting Services		
Salaries and wages	\$ 807,192	\$ 384,168	\$ 985,756	\$ 1,369,924	\$ 2,177,116	\$ 2,219,890
Employee benefits	138,259	65,802	168,844	234,646	372,905	400,734
Payroll taxes	50,045	23,818	61,116	84,934	134,979	139,684
	995,496	473,788	1,215,716	1,689,504	2,685,000	2,760,308
Fellowships awards	6,706,100	-	-	-	6,706,100	6,311,080
Sohn pediatric awards	8,526	-	-	-	8,526	378,368
Physician-scientist awards	1,437,476	-	-	-	1,437,476	2,195,228
Quantitative biology awards	544,705	-	-	-	544,705	2,154,471
Dale Frey awards	500,000	-	-	-	500,000	599,985
Clinical investigator awards	4,562,161	-	-	-	4,562,161	3,084,412
Rachleff innovation awards	2,448,977	-	-	-	2,448,977	3,991,936
Advisory committee and award panel services including donated services of \$396,000	514,098	-	-	-	514,098	529,425
Fellows retreat	3,462	-	-	-	3,462	110,098
Professional fees	131,490	62,580	160,578	223,158	354,648	646,549
Stationery and supplies	51,169	24,353	62,489	86,842	138,011	158,871
Telephone	11,367	5,410	13,881	19,291	30,658	29,849
Postage	7,141	3,399	8,721	12,120	19,261	29,128
Occupancy	133,315	63,449	162,807	226,256	359,571	357,111
Insurance	13,241	6,302	16,171	22,473	35,714	42,594
Printing and publications	-	44,582	114,397	158,979	158,979	200,483
Depreciation	14,544	6,923	17,761	24,684	39,228	39,272
Tax expense	-	(6,996)	-	(6,996)	(6,996)	-
Special events	-	-	6,595	6,595	6,595	51,794
Bad debt	-	183,000	-	183,000	183,000	11,901
Miscellaneous	9,702	4,616	11,848	16,464	26,166	56,099
Total operating expenses	18,092,970	871,406	1,790,964	2,662,370	20,755,340	23,738,962
Donated investment services	-	-	-	-	-	139,375
Donor benefit expenses: Theater tickets	-	-	460	460	460	270,928
Total expenses	\$ 18,092,970	\$ 871,406	\$ 1,791,424	\$ 2,662,830	\$ 20,755,800	\$ 24,149,265

See notes to financial statements.

Cancer Research Fund of the Damon Runyon–Walter Winchell Foundation

Statements of Cash Flows
Years Ended June 30, 2021 and 2020

	2021	2020
Cash flows from operating activities:		
Change in net assets	\$ 30,433,240	\$ (2,432,799)
Adjustments to reconcile increase (decrease) in net assets to net cash used in operating activities:		
Depreciation	39,228	39,272
Deferred rent obligation	(9,946)	2,887
Bad debt expense	183,000	11,901
Net realized and unrealized gains on investments	(31,219,476)	(1,857,481)
Change in value of perpetual and charitable remainder trusts	(1,561,889)	155,735
Settlement of charitable remainder trusts	(84,960)	-
Changes in operating assets and liabilities:	-	-
Increase (decrease) in accounts receivable	(41,730)	56,958
Decrease in interest and dividends receivable	12,000	196,723
Increase in prepaid expenses and other assets	(3,229)	(104,894)
Decrease (increase) in contributions and bequests receivable	116,076	(4,282,473)
Decrease in accounts payable and accrued expenses	(35,199)	(81,545)
(Decrease) increase in deferred revenue	(480,055)	1,037,209
Decrease in deposits for theater tickets	(200)	(10,213)
Decrease in fellowships and awards payable	(2,434,257)	(944,355)
Net cash used in operating activities	(5,087,397)	(8,213,075)
Cash flows from investing activities:		
Purchase of investments	(22,448,724)	(173,419,857)
Proceeds from sale of investments	26,217,023	193,170,180
Purchase of fixed assets	(1,120)	(1,886)
Net cash provided by investing activities	3,767,179	19,748,437
(Decrease) increase in cash and cash equivalents	(1,320,218)	11,535,362
Cash and cash equivalents:		
Beginning	14,909,769	3,374,407
Ending	\$ 13,589,551	\$ 14,909,769

See notes to financial statements.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 1. Organization and Summary of Significant Accounting Policies

The Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation, d/b/a Damon Runyon Cancer Research Foundation (the Foundation or Damon Runyon), was incorporated in 1947. Its mission is to accelerate breakthroughs by identifying the most brilliant, creative and driven young scientists and providing them with funding to pursue innovative new approaches to cancer because we need bold, fresh new ideas to conquer this complex set of diseases. Damon Runyon funds the most talented early career researchers working across the entire spectrum of research, from discovery science to clinical trials, with the goal of accelerating the translation of scientific discoveries into new ways to prevent or cure all forms of cancer. It's internationally recognized and highly competitive grant programs are designed to achieve these goals. Recipients of Damon Runyon awards have received the Nobel Prize and other prestigious awards, and are leaders in cancer research at the forefront of finding new cures.

Basis of accounting and financial statements presentation: The accompanying financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosures of contingencies at the date of the financial statements, and revenue and expenses recognized during the reporting period. Actual results could differ from those estimates.

Net asset classifications: Information about the Foundation's financial information and activities are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Foundation and changes therein are classified and reported as follows:

Net assets without donor restrictions: Net assets that are not subject to donor-imposed stipulations.

Net assets with donor restrictions: Net assets subject to donor-imposed stipulations that will be met either by actions of the Foundation or the passage of time.

Net assets held in perpetuity resulting from contributions and other inflows of assets whose use by the Foundation is limited by donor-imposed stipulations that must be maintained permanently by the Foundation or, in the case of perpetual trusts, by third parties. Generally, the donors of these assets permit the Foundation to use all or part of the income earned on related investments for program purposes.

Cash and cash equivalents: Cash and cash equivalents include highly liquid investments with a maturity of three months or less at time of purchase, except for those held by investment managers as part of their long-term investment strategy. The Foundation maintains cash in bank accounts which, at times, may exceed federally insured limits. The Foundation has not experienced any losses in such accounts.

Investments: Investments are reported at fair value in the balance sheets. Where applicable, investments are stated at net asset value (NAV) as a practical expedient to fair value. The statements of activities includes investment return greater than the amount appropriated for operations consisting of interest and dividend income, and realized and unrealized gains and losses. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Realized and unrealized gains and losses are recognized as changes in net assets in the periods in which they occur, and investment income is recognized as revenue in the period earned.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Fixed assets: Fixed assets are recorded at cost, if purchased, or fair value at date of gift, if donated. The Foundation capitalizes all purchases of fixed assets in excess of \$1,000. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets or, in the case of leasehold improvements, over the life of the lease, if shorter. Computer equipment and software and furniture and fixtures are depreciated over a five-year estimated useful life.

Revenue and support: Revenue is reported as increases in net assets without donor restrictions unless its use is limited by donor-imposed restrictions. Consistent with the Foundation's commitment in its solicitation materials and other publications, all bequests and contributions, with the exception of contributions received in connection with the sale of theater tickets and donated services, are restricted for scientific awards, unless otherwise restricted by the donor. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law.

Expirations of donor restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions.

Operations include all revenue earned and expenses incurred, including the amount of investment return required to equalize operating revenue and expenses. Investment return in excess of or less than such amount allocated to operations is reported as nonoperating activity.

Contributions, which include unconditional promises to give (pledges), are recognized as revenue in the period received. Conditional contributions are those contributions that contain donor-imposed rights of refund/return and barriers (performance obligations and/or controlling stipulations). Conditional contributions are recognized into revenue when conditions are satisfied and then follow the above policies for unconditional contributions. Bequests are recorded as revenue at the time that an unassailable right to the gift has been established by the probate court and the proceeds are measurable in amount.

Revenue other than contributions, are recognized in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers, which provides a five-step model for recognizing revenue from contracts with customers as follows:

- Identify the contract with the customer
- Identify the performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to the performance obligations in the contract
- Recognize the revenue when or as the performance obligations are satisfied

Special event and theater ticket revenue are considered as exchange transactions.

Special event performance obligation is to host the event to its registered attendees. Payments are received upon the event registration. Revenue is recognized at a point in time when the event takes place. There is deferred revenue recognized for special events in the amount of \$557,154 and \$1,037,029 as of June 30, 2021, and 2020, respectively.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Theater ticket performance obligation is to provide Broadway tickets to customers at the time of sale. Payments are received upon the receipt of the ticket and revenue is recognized at a point in time when the sale takes place. The foundation acts as an agent between the box-office and the customer and is not responsible to provide services, rescheduling, altering shows or refunding the money to the customer.

Contributions and bequests receivable are reported at their outstanding balances discounted to the net present value of their net realizable value based on a risk adjusted interest rate. The Foundation estimates an allowance for bad debts based on historical bad debt factors related to the donor's ability to pay and current economic trends. As of June 30, 2021 and 2020, management determined that no allowance was required.

The Foundation recognizes as income, donated services that require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if they had not been contributed.

Donor concentration: Approximately 16% and 37% of the total contributions and bequests revenue for the years ended June 30, 2021 and 2020, respectively, were provided by one donor. In addition, approximately 65% of the gross pledges and contributions receivable at June 30, 2021, were due from three donors and approximately 84% of the gross pledges and contributions receivable at June 30, 2020, were due from five donors.

Expenses: Expenses are reported as decreases in net assets without donor restrictions. The cost of providing the various program and supporting services of the Foundation have been summarized on a functional basis in the accompanying financial statements. Certain costs and expenses have been allocated between program services and supporting services on a reasonable basis as determined by management.

Fellowships and awards are recorded as an expense and a payable after they are reviewed by award selection committees, which are comprised of leading scientists, upon the approvals of the board of directors and acceptance of the award by the awardee. All fellowships and awards are usually expected to be paid within a four-year period or less.

Deferred revenue: Deferred revenue represents monies received in advance of special events expected to occur in the future, which will be recognized in the statements of activities when the events occur.

Fair value measurements: Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Pursuant to Financial Accounting Standards Board (FASB) ASC 820, level inputs are defined as follows:

Level 1: Inputs that reflect unadjusted quoted market prices in active markets for identical assets or liabilities that the Foundation has the ability to access at the measurement date, and where transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The types of investments in Level 1 generally include listed equities, mutual funds and exchange-traded funds.

Level 2: Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Inputs include quoted market prices for similar assets or liabilities in markets that are not active, markets in which there are few transactions, prices are not current or prices vary substantially over time. Investments in this category generally include corporate debt, U.S. government debt, and less liquid securities, such as securities traded on certain foreign exchanges, as well as alternative investments that can be redeemed in the near term.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

A significant adjustment to a Level 2 input could result in the Level 2 measurement becoming a Level 3 measurement.

Level 3: Inputs that are unobservable for the asset or liability and that include situations where there is little, if any, market activity for the asset or liability. The inputs into the determination of fair value are based upon the best information in the circumstances and may require significant management judgment or estimates. Investments in this category generally include equity and debt positions in private companies and real estate and ownership interests in alternative investments that cannot be redeemed in the near term.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The Foundation assesses the levels of the investments at each measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the transfer in accordance with its accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. There were no transfers during fiscal years 2021 and 2020.

Income taxes: The Foundation has been determined by the Internal Revenue Service to be a Section 501(c) (3) charitable organization exempt from federal income taxes under Section 501(a) of the Internal Revenue Code (the IRC). The Foundation has been classified as a publicly supported organization and not as a private foundation under Section 509(a) (1) of the IRC and qualifies for the maximum charitable contribution deduction by donors. As a nonprofit organization, the Foundation is subject to taxes on unrelated business income.

Management evaluated the Foundation's tax positions and concluded that the Foundation had taken no uncertain tax positions that require adjustment or disclosure to the financial statements. Generally, the Foundation is no longer subject to income tax examination by U.S. federal, state or local tax authorities for tax years before 2018, which is the standard statute of limitation look-back period.

Endowment: The Foundation's board of directors has determined that, when the Foundation receives a contribution and the donor restricts the Foundation from spending the principal, the Foundation is required to maintain the historical dollar value of the contribution received as an endowment. Such amount is recorded as net assets with donor restrictions.

The Foundation is subject to the New York Uniform Prudent Management of Institutional Funds Act (NYPMIFA), and has interpreted NYPMIFA as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. The remaining portion of the endowment fund is classified as net assets with donor restrictions until those amounts are appropriated for expenditure by the Foundation in a manner consistent with the standard of prudence prescribed by NYPMIFA.

Subsequent events: The Foundation evaluates events occurring after the date of the financial statements to consider whether or not the impact of such events needs to be reflected and/or disclosed in the financial statements. Such evaluation is performed through the date the financial statements are available for issuance, which was October 20, 2021, for these financial statements.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Risks and uncertainties: The Foundation invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts of investments reported in the balance sheets.

Recently issued accounting pronouncements: In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02, *Leases (Topic 842)*. The guidance in this ASU supersedes the leasing guidance in Topic 840, *Leases*. Under the new guidance, lessees are required to recognize lease assets and lease liabilities on the balance sheets for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statements of activities. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. In June 2020, the FASB issued ASU 2020-05, which delayed the effective date of ASU 2016-02, making it effective for annual reporting periods beginning after December 15, 2021. The Foundation is currently evaluating the impact of the adoption of the new standard on its financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation - disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This ASU requires a not-for-profit entity to present contributed nonfinancial assets in the statement of activities as a line item that is separate from contributions of cash or other financial assets. The term nonfinancial asset includes fixed assets, use of fixed assets or utilities, materials and supplies, intangible assets, services and unconditional promises of those assets. The ASU should be applied on a retrospective basis and is effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022. Early adoption is permitted. The Foundation is currently evaluating the impact of the adoption of the new standard on its financial statements.

Recently adopted accounting pronouncements: In August 2018, the FASB issued ASU 2018-13, *Fair Value Measurements (Topic 820): Disclosure Framework – Changing the Disclosure Requirement for Fair Value Measurement*. This ASU modifies the disclosure requirements for fair value measurements, and removes disclosures related to transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing transfers between levels, and the valuation process of Level 3 fair value measurements and a roll forward of Level 3 investments. Furthermore, entities are no longer required to estimate and disclose the timing of liquidity events for investments measured at fair value. Instead, the requirement to disclose such events applies only when they have been communicated to the reporting entities for fiscal years, and interim periods within those fiscal years, beginning after December 31, 2019. Early adoption is permitted. The Foundation has adopted this standard for the year ended June 30, 2021, which did not have an impact on its financial statements.

In June 2018, the FASB issued ASU 2018-08, *Not-For-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*. This ASU clarifies the guidance for evaluating whether a transaction is reciprocal (i.e., an exchange transaction) or nonreciprocal (i.e. a contribution) and for distinguishing between conditional and unconditional contributions. The ASU also clarifies the guidance used by entities other than not-for-profits to identify and account for contributions made. The ASU has different effective dates for resource recipients and resource providers. Additionally, the ASU provides for earlier effective dates for public business entities. As the Foundation is a resource recipient, the ASU is applicable to contributions received for annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Foundation has adopted this standard for contributions received for the year ended June 30, 2020, which did not have an impact on its financial statements and adopted this standard for contributions made for the year ended June 30, 2021, which also did not have an impact on its financial statements.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers (Topic 606)*, requiring an entity to recognize the amount of revenue which it expects to be entitled for the transfer of promised goods or services to customers. There was no impact on the timing of revenue recognition with the adoption of this ASU. Additional disclosures have been added in the revenue and support section above.

Note 2. Contributions and Bequests Receivable, Net

Contributions and bequests receivable at June 30, 2021 and 2020, are due to be collected as follows:

	2021	2020
Less than one year	\$ 3,697,666	\$ 4,310,325
One to five years	7,252,206	6,961,500
	10,949,872	11,271,825
Discount to present value at 2% – 3%	(239,729)	(262,606)
	<u>\$ 10,710,143</u>	<u>\$ 11,009,219</u>

Note 3. Investments

Investments, at fair value, consist of the following at June 30, 2021 and 2020:

	2021	2020
Money market funds	\$ 1,954,826	\$ 2,315,061
Marketable equity mutual and exchange-traded funds	107,130,312	75,813,420
Marketable exchange traded fixed income fund	24,712,875	29,582,087
Marketable debt securities	425	425
Fixed term certificate of deposit	144,563	144,529
Limited partnerships	8,647,767	7,284,069
	<u>\$ 142,590,768</u>	<u>\$ 115,139,591</u>

Income generated from the Foundation's investments for the years ended June 30, 2021 and 2020, is as follows:

	2021	2020
Interest and dividends	\$ 2,177,954	\$ 2,883,721
Net appreciation in fair value of investments	31,219,476	1,857,481
Donated investment services	-	(139,375)
Investment expenses	(153,601)	(66,701)
	33,243,829	4,535,126
Investment gain allocated to operations	(3,954,938)	(4,151,352)
	<u>\$ 29,288,891</u>	<u>\$ 383,774</u>

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 3. Investments (Continued)

The income from investments is reported in the statements of activities, as follows:

	2021		
	Without Donor Restrictions	With Donor Restrictions	Total
Operating activities:			
Investment return allocated to operations	\$ 3,954,938	\$ -	\$ 3,954,938
Nonoperating activities:			
Investment return greater than amount appropriated for operations	27,127,655	2,161,236	29,288,891
Total	<u>\$ 31,082,593</u>	<u>\$ 2,161,236</u>	<u>\$ 33,243,829</u>
	2020		
	Without Donor Restrictions	With Donor Restrictions	Total
Operating activities:			
Investment return allocated to operations	\$ 4,151,352	\$ -	\$ 4,151,352
Nonoperating activities:			
Investment return greater than amount appropriated for operations	-	383,774	383,774
Total	<u>\$ 4,151,352</u>	<u>\$ 383,774</u>	<u>\$ 4,535,126</u>

Note 4. Fair Value Measurements and Disclosures

Fair value of financial instruments: The following methods and assumptions were used in estimating the fair values of significant financial instruments at June 30, 2021 and 2020:

Investments: The fair value is determined as described below.

Amounts held in trust by others: The carrying amount, which approximates fair value, is based on the Foundation's share in the fair value of the underlying assets of the perpetual trusts and on the estimated present value of the anticipated cash inflows from the charitable remainder trusts.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 4. Fair Value Measurements and Disclosures (Continued)

Fair value measurements: The following tables present the Foundation's fair value hierarchy for those assets measured at fair value on a recurring basis as of June 30, 2021 and 2020:

Description	Total	2021		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
Investments:				
Marketable equity ETF funds	\$ 107,130,312	\$ 107,130,312	\$ -	\$ -
Marketable exchange traded fixed income fund	24,712,875	24,712,875	-	-
Marketable debt securities	425	-	425	-
Money market	1,954,826	1,954,826	-	-
Total investments	133,798,438	\$ 133,798,013	\$ 425	\$ -
Certificates of deposits	144,563			
Limited partnerships ⁽¹⁾	8,647,767			
	<u>\$ 142,590,768</u>			
Amounts held in trust by others	\$ 8,033,216	\$ -	\$ -	\$ 8,033,216
2020				
Description	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Other Unobservable Inputs (Level 3)
Investments:				
Marketable equity ETF funds	\$ 75,813,420	\$ 75,813,420	\$ -	\$ -
Marketable exchange traded fixed income fund	29,582,087	29,582,087	-	-
Marketable debt securities	425	-	425	-
Money market	2,315,061	2,315,061	-	-
Total investments	107,710,993	\$ 107,710,568	\$ -	\$ -
Certificates of deposits	144,529			
Limited partnerships ⁽¹⁾	7,284,069			
	<u>\$ 115,139,591</u>			
Amounts held in trust by others	\$ 6,386,367	\$ -	\$ -	\$ 6,386,367

(1) In accordance with the Fair Value Measurement topic, certain investments that are measured at fair value using the NAV per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the balance sheets.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Foundation's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment. Below are the valuation techniques used by the Foundation to measure different financial instruments at fair value.

Marketable equity securities and money market funds listed on a national securities exchange are stated at the last reported sales or trade price on the day of valuation.

Marketable debt securities, U.S. government debt, and non-U.S. government debt are valued based on the last reported bid or evaluation price provided by broker-dealers.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 4. Fair Value Measurements and Disclosures (Continued)

Investments in limited partnerships are valued at fair value based on the applicable percentage ownership of the limited partnerships' net assets as of the measurement date, as reported to the Foundation by the limited partnerships. In determining fair value, the Foundation utilized, as a practical expedient, the net asset value provided by the limited partnerships. The limited partnerships value securities and other financial instruments on a fair value basis of accounting. The estimated fair values of certain investments of the limited partnerships, which may include private placements and other securities for which prices are not readily available, are determined by the general partner or sponsor of the respective limited partnership and may not be realized. Accordingly, the estimated fair values may differ significantly from the values that would have been used had a ready market existed for these investments.

Amounts held in trust by others consist of the Foundation's interest in several perpetual trusts and charitable remainder trusts. The fair value of the Foundation's interest in perpetual trusts is based on the fair value of the underlying trust assets. The fair value of the Foundation's interest in charitable remainder trusts is determined at the net present value of the anticipated cash inflows, discounted at interest rates ranging from 6.0% to 8.0%, using actuarially based mortality tables, as described in Note 5.

Financial instruments classified as Level 3 in the fair value hierarchy represent the Foundation's investments in financial instruments in which the Foundation has used at least one significant unobservable input in the valuation model. The following table presents a reconciliation of activity for the Level 3 financial instruments for the years ended June 30, 2021 and 2020:

	2021		
	Non-U.S. Government Debts	Amounts Held in Trust by Others	Total
Beginning balance, July 1	\$ -	\$ 6,386,367	\$ 6,386,367
Purchase/redemption of non-U.S. government debt	-	84,960	84,960
Change in unrealized depreciation	-	1,561,889	1,561,889
Ending balance, June 30	\$ -	\$ 8,033,216	\$ 8,033,216

	2020		
	Non-U.S. Government Debts	Amounts Held in Trust by Others	Total
Beginning balance, July 1	\$ 150,178	\$ 6,542,102	\$ 6,692,280
Purchase/redemption of non-U.S. government debt	(112,399)	-	(112,399)
Realized loss on bond sale	(37,779)	-	(37,779)
Change in unrealized depreciation	-	(155,735)	(155,735)
Ending balance, June 30	\$ -	\$ 6,386,367	\$ 6,386,367

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 4. Fair Value Measurements and Disclosures (Continued)

The following table provides additional information on the investments in limited partnerships as of June 30, 2021 and 2020:

Investment Objective	2021	Redemption Frequency	Redemption Notice Period
Long-short master fund ^(a)	\$ 8,647,767	Monthly	30 days

Investment Objective	2020	Redemption Frequency	Redemption Notice Period
Long-short master fund ^(a)	\$ 7,284,069	Monthly	30 days

(a) This category seeks performance target and not a guide to portfolio construction.

As of June 30, 2021 and 2020, there were no unfunded commitments related to any of the investments in limited partnership held by the Foundation.

The following table presents quantitative information about Level 3 fair value measurements as of June 30:

	Fair Value		Valuation Technique	Unobservable Inputs	Range of Inputs
	2021	2020			
Beneficial interest in perpetual trust	\$ 6,597,948	\$ 5,222,572	Market approach based on underlying marketable securities	None	N/A
Charitable gift annuities	\$ 1,435,268	\$ 1,163,795	Value of underlying assets and present value techniques	Rate of return Discount rate Life expectancy	6% 6.1% – 7.2%

Note 5. Amounts Held in Trust by Others

The Foundation is named as beneficiary of several perpetual trusts and charitable remainder trusts. The Foundation does not exercise control over the trusts' assets, which are administered by third parties. In some of the charitable remainder trusts, the Foundation is currently receiving income as one of the named beneficiaries.

The perpetual trusts are reported in the net assets with donor restrictions because the Foundation has an irrevocable right to all or, in cases where other beneficiaries participate, a portion of the income earned on the trusts' assets in perpetuity, but will never receive the assets held in trust.

For those trusts in which the Foundation has a remainder interest (i.e., upon termination of the trusts), the Foundation will receive the assets remaining in the trusts (or a portion thereof in those cases where other beneficiaries participate), which are reported in the net assets with donor restrictions at the present value of the estimated future benefit to be received when the trusts are distributed. The discount rate ranges from 6.00% to 8.00%.

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 5. Amounts Held in Trust by Others (Continued)

The amounts held in trust by others are adjusted annually to reflect changes in the life expectancy of the beneficiaries, the value of the assets held in the trusts and other changes in estimates of future payments. Such adjustments are reported as a change in value of charitable remainder trusts in the statements of activities. The reported value is measured by the fair value of the trusts' assets net of the present value of estimated future payments to beneficiaries.

The Foundation has also been named as beneficiary of several other trusts that have not been included in these financial statements because they have very broad power to invade, which causes uncertainty in determining the value to the Foundation in the future, or the future benefit to the Foundation is deemed to be minimal because of the ages of the life beneficiaries.

Note 6. Fixed Assets

Fixed assets at June 30, 2021 and 2020, consist of the following:

	2021	2020
Leasehold improvements	\$ 376,804	\$ 376,804
Computer equipment and software	381,304	380,184
Furniture and fixtures	238,616	238,616
	<u>996,724</u>	<u>995,604</u>
Less accumulated depreciation	(797,031)	(757,803)
	<u>\$ 199,693</u>	<u>\$ 237,801</u>

Note 7. Liquidity and Availability of Financial Assets

The Foundation receives substantial donor restricted gifts as contributions with donor time and purpose restrictions. The income generated from donor restricted endowments may be donor restricted or without restrictions as to use. In addition, the Foundation receives support without donor restrictions; such support has historically represented approximately 53% of annual program funding needs, with the remainder funded by investment income without donor restrictions and appropriated earnings from gifts with donor restrictions.

Investment income without donor restrictions, earnings appropriated from endowments with donor restrictions, contributions without donor restrictions and contributions with donor restrictions for use in current activities and programs are considered to be available to meet cash needs for general expenditures. General expenditures include administrative and general expenses, fundraising expenses and grant commitments expected to be paid in the subsequent year. Annual operations are defined as activities occurring during, and included in the budget for, a fiscal year.

The Foundation manages its cash available to meet general expenditures following three guiding principles:

- Operating within a prudent range of financial soundness and stability
- Maintaining a sufficient level of asset liquidity
- Monitoring and maintaining reserves to provide reasonable assurance that long-term grant commitments and obligations related to endowments with donor restrictions and quasi endowments will continue to be met

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 7. Liquidity and Availability of Financial Assets (Continued)

The Foundation's Scientific Committees (the Committees) meet semi-annually to review and approve grant requests. As a result, the Foundation has a liquidity policy to maintain financial assets available to meet general expenditures at a level that represents 100% of annual expenses for administrative and general expenses, as well as fundraising expenses, plus an amount that represents the next expected payment for semi-annual grant commitments approved by the Committees, which typically represents approximately 50% of the expected annual grant cash needs. To achieve this, the Foundation forecasts its future cash flows and monitors its liquidity quarterly.

	2021	2020
Financial assets at year-end:		
Cash and cash equivalents	\$ 13,589,551	\$ 14,909,769
Accounts receivable	171,976	130,246
Contributions and bequests receivable, net	10,710,143	11,009,219
Interest and dividends receivable	-	12,000
Other long-term investments	142,590,768	115,139,591
Total financial assets at year-end	<u>\$ 167,062,438</u>	<u>\$ 141,200,825</u>

Financial assets available to meet general expenditures over the next 12 months:

Cash and cash equivalents	\$ 13,589,551	\$ 14,909,769
Accounts receivable	171,976	130,246
Contributions for operations due in one year or less	3,644,666	4,310,325
Interest and dividends receivable	-	12,000
	<u>\$ 17,406,193</u>	<u>\$ 19,362,340</u>

The Foundation has a board designated endowment totaling \$131,395,321 as of June 30, 2021, and \$105,602,910 as of June 30, 2020. Although the Foundation does not intend to spend from its board designated endowment other than amounts appropriated for general expenditures as part of its annual budget approval and appropriation process, amounts from its board designated endowment could be made available if necessary.

Note 8. Fellowships and Awards Payable

Fellowships and awards payable as of June 30, 2021, are expected to be paid as follows:

	2021
Years ending June 30:	
2022	\$ 15,200,334
2023	9,117,000
2024	5,122,000
2025	1,575,000
	<u>31,014,334</u>
Discount to present value at 2.0% – 3.0%	<u>(663,911)</u>
	<u>\$ 30,350,423</u>

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 9. Pension Plan

The Foundation has a defined-contribution plan covering substantially all of its employees. The Foundation's policy is to contribute 10% of employees' base compensation after two full years of full-time employment. Total pension expense for fiscal years 2021 and 2020, was approximately \$143,000 and \$138,000, respectively.

Note 10. Net Assets With Donor Restrictions

Net assets with donor restrictions as of June 30, 2021 and 2020, consist of the following:

	2021	2020
Charitable remainder trusts	\$ 1,435,268	\$ 1,163,795
Dale Frey award for breakthrough scientists	10,795,240	9,159,725
Wetchler award for scientists	133,545	110,324
Perpetual trusts – held in perpetuity	6,597,948	5,222,572
Contributions with donor restrictions – held in perpetuity	266,662	266,662
	<u>\$ 19,228,663</u>	<u>\$ 15,923,078</u>

Net assets released from donor restrictions during the years ended June 30, 2021 and 2020, by incurring expenses satisfying the restricted purposes or by the occurrence of other events specified by the donors, are as follows:

	2021	2020
Scientific awards:		
Fellowships awards	\$ 6,470,961	\$ 5,835,020
Sohn pediatric awards	8,526	378,368
Physician-scientist awards	1,437,476	2,195,228
Dale Frey awards	500,000	599,985
Clinical investigator awards	4,562,161	3,084,412
Rachleff innovation awards	2,448,977	3,991,936
	<u>\$ 15,428,101</u>	<u>\$ 16,084,949</u>

Net assets held in perpetuity consist almost entirely of perpetual trusts held by third-party trustees (see Note 5).

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 11. Lease Commitment

The Foundation holds a long-term lease for office space which expires on April 30, 2029, and is subject to rent escalations with nine months' rent credit provided. The future minimum lease payments under this lease are as follows:

Years ending June 30:	
2022	\$ 350,000
2023	350,000
2024	382,083
2025	385,000
2026	385,000
Thereafter	1,090,834
	<u>\$ 2,942,917</u>

The lease is subject to escalations for the Foundation's pro rata share of the increase in real estate taxes and operating expenses.

Deferred rent consists of the excess of the rental expenses on a straight-line basis over the payments required by the lease. As of June 30, 2021 and 2020, there was \$288,298 and \$298,244, respectively, of deferred rent included in accounts payable and accrued expenses. Leasehold improvements related to the lease of \$240,000 were capitalized and are being amortized over the life of the lease. The value of the improvements is being amortized through rent expense and a deferred charge as of June 30, 2021 and 2020, of \$162,302 and \$183,022, respectively, is in accounts payable and accrued expenses on the balance sheets.

Rent expense was approximately \$360,000 and \$357,000 for the years ended June 30, 2021 and 2020, respectively.

As part of the Foundation's lease agreement, the Foundation obtained an active letter of credit, which is collateralized by a 12-month certificate of deposit amounting to \$108,261 and \$108,240 at June 30, 2021 and 2020, respectively, that is included in investments in lieu of a cash security deposit.

Note 12. Endowment Fund

The Foundation manages its investment portfolio to generate income to be used to support operating and program activities. The Foundation has implemented investment policies with a goal to provide a predictable stream of funding while seeking to maintain its purchasing power. These investment portfolio assets are designated by the Foundation for long-term investment and include available financial resources that are predominantly unrestricted by donors or are available to fund fellowships and awards payable. Under the oversight of the Board's Investments Committee, portfolio assets are invested in a manner that is intended to produce results that provide a high total return (income and capital gains) over the long term, consistent with the preservation of principal. The Foundation expects that earnings growth will match or exceed inflation and that the real (i.e., inflation-adjusted) value of the investment portfolio will be maintained. Actual returns in any given year may vary.

To satisfy its long-term rate-of-return objectives, the Foundation relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends).

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 12. Endowment Fund (Continued)

The Foundation prepares an annual budget that is reviewed and approved by the board of directors. Projected revenues are compared to projected expenditures. When projected expenditures exceed projected revenues, the board of directors authorizes a drawdown from the endowment to balance the budget. The current benchmark used is 5.5% on a three-year rolling average. In any given year, the actual drawdown may be more or less than the 5.5% depending on operational considerations.

On the statements of activities, approximately \$3,950,000 and \$4,151,000 for the years ended June 30, 2021 and 2020, respectively, are reflected as investment return allocated to operations. Consistent with the policy of the board of directors, this amount represents the funds needed to balance unrestricted revenues and expenses on an accrual basis of accounting.

Endowment assets are represented by available funds allocated by the Foundation for long-term investment and funds received from donors for funding of scientific awards that are included in net assets with donor restrictions.

	2021		
	Without Donor Restrictions	With Donor Restrictions	Total
Endowment assets, beginning of year	\$ 105,602,910	\$ 9,536,681	\$ 115,139,591
Investment return:			
Investment income	1,892,746	131,607	2,024,353
Net appreciation	29,189,847	2,029,629	31,219,476
Total investment return	31,082,593	2,161,236	33,243,829
Other changes during the year:			
Contributions	1,241,050	5,157,715	6,398,765
Withdrawals	(11,688,917)	(502,500)	(12,191,417)
Total contributions/withdrawals	(10,447,867)	4,655,215	(5,792,652)
Release from restriction	5,157,685	(5,157,685)	-
Endowment assets, end of year	\$ 131,395,321	\$ 11,195,447	\$ 142,590,768

	2020		
	Without Donor Restrictions	With Donor Restrictions	Total
Endowment assets, beginning of year	\$ 123,277,017	\$ 9,755,416	\$ 133,032,433
Investment return:			
Investment income	2,457,222	220,423	2,677,645
Net appreciation	1,694,130	163,351	1,857,481
Total investment return	4,151,352	383,774	4,535,126
Other changes during the year:			
Contributions	139,375	1,932,657	2,072,032
Withdrawals	(23,897,515)	(602,485)	(24,500,000)
Total contributions/withdrawals	(23,758,140)	1,330,172	(22,427,968)
Release from restriction	1,932,681	(1,932,681)	-
Endowment assets, end of year	\$ 105,602,910	\$ 9,536,681	\$ 115,139,591

Cancer Research Fund of the Damon Runyon—Walter Winchell Foundation

Notes to Financial Statements

Note 13. Donated Services

The Foundation received donated services for the years ended June 30, 2021 and 2020, as follows:

	2021	2020
Investment management services	\$ -	\$ 139,375
Members of scientific selection committee	396,000	357,000
	<u>\$ 396,000</u>	<u>\$ 496,375</u>